Pharmaceutical

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

Dec 24, 2023 - 18:00
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.
Read the original article

Tags:

Previous Article

STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease

Next Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How six trends are driving pharmaceutical milling  

How six trends are driving pharmaceutical milling  

May 9, 2024

STAT+: New Medicare Advantage rule is boon for providers, drag on insurers

STAT+: New Medicare Advantage rule is boon for provider...

Feb 5, 2024

Japan grants patent for BioArctic’s Parkinson’s disease antibody

Japan grants patent for BioArctic’s Parkinson’s disease...

Aug 24, 2023